NASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free VTYX Stock Alerts $7.98 +0.28 (+3.64%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$7.27▼$8.1250-Day Range$1.90▼$10.1352-Week Range$1.87▼$41.00Volume1.11 million shsAverage Volume9.77 million shsMarket Capitalization$472.82 millionP/E RatioN/ADividend YieldN/APrice Target$22.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Ventyx Biosciences alerts: Email Address Ventyx Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside172.6% Upside$21.75 Price TargetShort InterestBearish19.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 27 Articles This WeekInsider TradingSelling Shares$162,155 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.55) to ($2.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.25 out of 5 starsMedical Sector604th out of 946 stocksPharmaceutical Preparations Industry274th out of 430 stocks 3.3 Analyst's Opinion Consensus RatingVentyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.75, Ventyx Biosciences has a forecasted upside of 172.6% from its current price of $7.98.Amount of Analyst CoverageVentyx Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted19.53% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ventyx Biosciences has recently increased by 64.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTYX. Previous Next 2.9 News and Social Media Coverage News SentimentVentyx Biosciences has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Ventyx Biosciences this week, compared to 4 articles on an average week.Search Interest53 people have searched for VTYX on MarketBeat in the last 30 days. This is an increase of 2,550% compared to the previous 30 days.MarketBeat Follows18 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $162,155.00 in company stock.Percentage Held by Insiders24.39% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ventyx Biosciences are expected to grow in the coming year, from ($2.55) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Ventyx Biosciences Stock (NASDAQ:VTYX)Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.Read More VTYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTYX Stock News HeadlinesMarch 18, 2024 | businesswire.comRobbins LLP Urges VTYX Investors with Large Losses to Contact the Firm Before April 30, 2024, for Information About Their RightsMarch 18, 2024 | msn.comTrump gets burned after touching on Social SecurityMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 17, 2024 | stockhouse.comVTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action LawsuitMarch 17, 2024 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarch 16, 2024 | finance.yahoo.comVTYX Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comVTYX Apr 2024 10.000 putMarch 15, 2024 | prnewswire.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYXMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 15, 2024 | prnewswire.comVentyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXMarch 15, 2024 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Up 64.4% in FebruaryMarch 14, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)March 14, 2024 | americanbankingnews.comVentyx Biosciences (NASDAQ:VTYX) Stock Price Up 5%March 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ventyx Biosciences on Strong Clinical Pipeline and Promising Drug DevelopmentsMarch 13, 2024 | markets.businessinsider.comShareholders that lost money on Ventyx Biosciences, Inc. (VTYX) should contact Levi & Korsinsky about pending Class Action - VTYXMarch 13, 2024 | americanbankingnews.comVentyx Biosciences (NASDAQ:VTYX) Upgraded by Wells Fargo & Company to OverweightMarch 13, 2024 | americanbankingnews.comVentyx Biosciences (NASDAQ:VTYX) Upgraded by Oppenheimer to OutperformMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Ventyx Biosciences’ Promising Clinical Advances and Strategic Position for Market OpportunitiesMarch 12, 2024 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)March 12, 2024 | msn.comVentyx rebounds as Oppenheimer upgrades after pipeline updatesMarch 12, 2024 | prnewswire.comVentyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYXMarch 12, 2024 | businesswire.comVTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!March 12, 2024 | prnewswire.comVTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!March 12, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx BiosciencesMarch 11, 2024 | msn.comWhat's Going On With Autoimmune/Inflammatory Disorder-Focused Ventyx Biosciences On Monday?March 11, 2024 | stockhouse.comPomerantz Law Firm Announces the Filing of a Class Action Against Ventyx Biosciences, Inc. and Certain Officers - VTYXMarch 11, 2024 | globenewswire.comVentyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor EventSee More Headlines Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/18/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VTYX CUSIPN/A CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees79Year FoundedN/APrice Target and Rating Average Stock Price Target$21.75 High Stock Price Target$62.00 Low Stock Price Target$5.00 Potential Upside/Downside+184.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.58% Return on Assets-57.42% Debt Debt-to-Equity RatioN/A Current Ratio11.87 Quick Ratio11.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book1.93Miscellaneous Outstanding Shares59,250,000Free Float44,800,000Market Cap$472.82 million OptionableOptionable Beta0.36 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Sheila K. Gujrathi M.D. (Age 54)Executive Chairperson Comp: $125kDr. Raju S. Mohan Ph.D. (Age 67)Founder, CEO, President & Director Comp: $989.99kDr. John M. Nuss Ph.D. (Age 65)Chief Scientific Officer Comp: $656.99kDr. Martin Douglas Auster M.D. (Age 49)Chief Financial Officer Mr. Christopher W. Krueger J.D. (Age 56)MBA, Chief Business Officer Comp: $568.14kKey CompetitorsMarinus PharmaceuticalsNASDAQ:MRNSNuvation BioNYSE:NUVBPhibro Animal HealthNASDAQ:PAHCArbutus BiopharmaNASDAQ:ABUSGH ResearchNASDAQ:GHRSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,079,254 shares on 3/11/2024Ownership: 6.315%Goldman Sachs Group Inc.Sold 252,757 shares on 3/1/2024Ownership: 2.300%GSA Capital Partners LLPBought 221,185 shares on 2/16/2024Ownership: 0.375%Price T Rowe Associates Inc. MDSold 3,623,237 shares on 2/16/2024Ownership: 0.344%Prelude Capital Management LLCBought 28,000 shares on 2/15/2024Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions VTYX Stock Analysis - Frequently Asked Questions Should I buy or sell Ventyx Biosciences stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VTYX shares. View VTYX analyst ratings or view top-rated stocks. What is Ventyx Biosciences' stock price target for 2024? 9 Wall Street analysts have issued 12 month price targets for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they expect the company's stock price to reach $21.75 in the next twelve months. This suggests a possible upside of 172.6% from the stock's current price. View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts. How have VTYX shares performed in 2024? Ventyx Biosciences' stock was trading at $2.47 on January 1st, 2024. Since then, VTYX stock has increased by 223.1% and is now trading at $7.98. View the best growth stocks for 2024 here. Are investors shorting Ventyx Biosciences? Ventyx Biosciences saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 9,190,000 shares, an increase of 64.4% from the February 14th total of 5,590,000 shares. Based on an average daily volume of 4,450,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 19.5% of the shares of the company are short sold. View Ventyx Biosciences' Short Interest. When is Ventyx Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VTYX earnings forecast. How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.08. During the same period in the previous year, the company posted ($0.62) EPS. What ETFs hold Ventyx Biosciences' stock? ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Alger Mid Cap 40 ETF (FRTY), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares U.S. Pharmaceuticals ETF (IHE). When did Ventyx Biosciences IPO? (VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share. Who are Ventyx Biosciences' major shareholders? Ventyx Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.34%), Vanguard Group Inc. (6.32%), Capital International Investors (3.99%), Goldman Sachs Group Inc. (2.31%), Goldman Sachs Group Inc. (2.30%) and Opaleye Management Inc. (1.93%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White. View institutional ownership trends. How do I buy shares of Ventyx Biosciences? Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VTYX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.